Finally moving forward in adult ALL

Research output: Contribution to journalComment/debate

1 Citation (Scopus)

Abstract

In this issue of Blood, Dhédin et al from the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) show that young to middle-aged adults who receive a pediatric-intensive chemotherapy regimen for treatment of Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph-neg ALL) do not appear to require an allogeneic stem cell transplant (alloSCT) if they achieve a good response on minimal residual disease (MRD) testing after induction therapy. Patients who are not good MRD responders however, achieve better outcomes with alloSCT than their counterparts who do not receive alloSCT.

Original languageEnglish (US)
Pages (from-to)2453-2454
Number of pages2
JournalBlood
Volume125
Issue number16
DOIs
StatePublished - Apr 16 2015

Fingerprint

Transplants
Stem cells
Stem Cells
Residual Neoplasm
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Philadelphia Chromosome
Pediatrics
Chemotherapy
Chromosomes
Blood Group Antigens
Drug Therapy
Testing
Therapeutics
Research

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology
  • Medicine(all)

Cite this

Finally moving forward in adult ALL. / Litzow, Mark R.

In: Blood, Vol. 125, No. 16, 16.04.2015, p. 2453-2454.

Research output: Contribution to journalComment/debate

Litzow, Mark R. / Finally moving forward in adult ALL. In: Blood. 2015 ; Vol. 125, No. 16. pp. 2453-2454.
@article{1e436f7e567245eabbb3238a51b3f07e,
title = "Finally moving forward in adult ALL",
abstract = "In this issue of Blood, Dh{\'e}din et al from the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) show that young to middle-aged adults who receive a pediatric-intensive chemotherapy regimen for treatment of Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph-neg ALL) do not appear to require an allogeneic stem cell transplant (alloSCT) if they achieve a good response on minimal residual disease (MRD) testing after induction therapy. Patients who are not good MRD responders however, achieve better outcomes with alloSCT than their counterparts who do not receive alloSCT.",
author = "Litzow, {Mark R}",
year = "2015",
month = "4",
day = "16",
doi = "10.1182/blood-2015-02-623793",
language = "English (US)",
volume = "125",
pages = "2453--2454",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "16",

}

TY - JOUR

T1 - Finally moving forward in adult ALL

AU - Litzow, Mark R

PY - 2015/4/16

Y1 - 2015/4/16

N2 - In this issue of Blood, Dhédin et al from the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) show that young to middle-aged adults who receive a pediatric-intensive chemotherapy regimen for treatment of Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph-neg ALL) do not appear to require an allogeneic stem cell transplant (alloSCT) if they achieve a good response on minimal residual disease (MRD) testing after induction therapy. Patients who are not good MRD responders however, achieve better outcomes with alloSCT than their counterparts who do not receive alloSCT.

AB - In this issue of Blood, Dhédin et al from the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) show that young to middle-aged adults who receive a pediatric-intensive chemotherapy regimen for treatment of Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph-neg ALL) do not appear to require an allogeneic stem cell transplant (alloSCT) if they achieve a good response on minimal residual disease (MRD) testing after induction therapy. Patients who are not good MRD responders however, achieve better outcomes with alloSCT than their counterparts who do not receive alloSCT.

UR - http://www.scopus.com/inward/record.url?scp=84927729448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927729448&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-02-623793

DO - 10.1182/blood-2015-02-623793

M3 - Comment/debate

C2 - 25883226

AN - SCOPUS:84927729448

VL - 125

SP - 2453

EP - 2454

JO - Blood

JF - Blood

SN - 0006-4971

IS - 16

ER -